These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 20869423)

  • 21. New developments in tyrosine kinase inhibitor therapy for newly diagnosed chronic myeloid leukemia.
    le Coutre P; Schwarz M; Kim TD
    Clin Cancer Res; 2010 Mar; 16(6):1771-80. PubMed ID: 20197479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Molecular-target therapy of Ph-positive leukemia by imatinib (tyrosine kinase inhibitor)].
    Tauchi T; Ohyashiki K
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1065-70. PubMed ID: 12938259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
    Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V
    Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic myeloid leukemia: reversing the chronic phase.
    Goldman JM
    J Clin Oncol; 2010 Jan; 28(3):363-5. PubMed ID: 20008612
    [No Abstract]   [Full Text] [Related]  

  • 25. [Cytogenetic response as a marker of efficacy of chronic myeloid leukemia therapy with a BCR-ABL thyrosine kinase inhibitor glivek].
    Turkina AG; Kruglov SS; Druzhkova GA; Domracheva EV; Zakharova AV; Vinogradova OIu; Sysoeva EP; Diachenko LV; Chelysheva EIu; Zakharova ES; Abakumov EM; Kolosheĭnova TI; Kolosova LIu; Ivanova TV; Zhuravlev VS; Nemchenko IS; Zingerman BV; Kurova ES; Triputen' NZ; Loriia SS; Kovaleva LG; Khoroshko ND
    Ter Arkh; 2005; 77(7):42-7. PubMed ID: 16116908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CML: imatinib mesylate (Glivec) or something else?
    Ghosh A
    Nepal Med Coll J; 2007 Dec; 9(4):292. PubMed ID: 18298026
    [No Abstract]   [Full Text] [Related]  

  • 27. Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia.
    Kaur G; Gazit A; Levitzki A; Stowe E; Cooney DA; Sausville EA
    Anticancer Drugs; 1994 Apr; 5(2):213-22. PubMed ID: 8049505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
    J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety.
    Perrone S; Massaro F; Alimena G; Breccia M
    Expert Opin Pharmacother; 2016 Aug; 17(11):1517-26. PubMed ID: 27231757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pregnancies in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitor.
    Zhou L; You JH; Wu W; Li JM; Shen ZX; Wang AH
    Leuk Res; 2013 Oct; 37(10):1216-21. PubMed ID: 23937984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular monitoring of tyrosine kinase inhibitor therapy of chronic myeloid leukemia in China.
    Jiang Q; Gale RP
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1549-55. PubMed ID: 27085530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Paradoxical MAPK-activation in response to treatment with tyrosine kinase inhibitors in CML: flow cytometry loses track.
    Schnetzke U; Fischer M; Frietsch JJ; Finkensieper A; Clement JH; Hochhaus A; La Rosée P
    Cytometry B Clin Cytom; 2014 Jul; 86(4):229-35. PubMed ID: 23576291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: assessment and management of cardiovascular risk factors.
    Ross DM; Arthur C; Burbury K; Ko BS; Mills AK; Shortt J; Kostner K
    Intern Med J; 2018 Feb; 48 Suppl 2():5-13. PubMed ID: 29388307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors.
    Breccia M; Stagno F; Gozzini A; Abruzzese E; Latagliata R; Rossi AR; Sorà F; Porrini R; Vigneri P; Trawinska M; Montefusco E; Sica S; Specchia G; Santini V; Alimena G
    Am J Hematol; 2011 Jun; 86(6):523-5. PubMed ID: 21594891
    [No Abstract]   [Full Text] [Related]  

  • 35. Increased values of the circulating PDGFβ sustains the "withdrawal syndrome" after tyrosine kinase inhibitor discontinuation in patients affected by chronic myeloid leukemia.
    Galimberti S; Fontanelli G; Barsotti S; Ricci F; Guerrini F; Baratè C
    Blood Cells Mol Dis; 2015 Oct; 55(3):211-2. PubMed ID: 26227847
    [No Abstract]   [Full Text] [Related]  

  • 36. Flow cytometric monitoring of the in vitro inhibition of the phosphorylation of CRKL and of SRC family kinases in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors.
    Krupkova L; Mojzikova R; Novotny J; Gazdova J; Divoka M; Skoumalova I; Rohon P; Jarosova M; Indrak K; Faber E; Divoky V
    Int J Lab Hematol; 2015 Feb; 37(1):e11-5. PubMed ID: 24845482
    [No Abstract]   [Full Text] [Related]  

  • 37. [Novelties and experience with tyrosine kinase inhibitor therapy in chronic myeloid leukemia].
    Gaál-Weisinger J; Mucsi O; Körösmezey G; Szili B; Eid H; Kiss R; Bödör C; Tárkányi I; Nagy Z; Demeter J
    Magy Onkol; 2017 Mar; 61(1):67-74. PubMed ID: 28273190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovering gene expression signatures responding to tyrosine kinase inhibitor treatment in chronic myeloid leukemia.
    Cha K; Li Y; Yi GS
    BMC Med Genomics; 2016 Aug; 9 Suppl 1(Suppl 1):29. PubMed ID: 27534394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Curing chronic myeloid leukemia.
    Rea D; Rousselot P; Guilhot J; Guilhot F; Mahon FX
    Curr Hematol Malig Rep; 2012 Jun; 7(2):103-8. PubMed ID: 22410764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Can chronic myeloid leukemia be cured by tyrosine kinase inhibitor?].
    Li MQ; Liu ZG
    Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):725-8. PubMed ID: 23978030
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.